Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...

Hims & Hers saw a massive YTD surge, but FDA news led to a pullback. Find out why HIMS stock is still undervalued and why ...

Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's ...

Although the telemedicine company displayed blistering growth and issued robust guidance, shares of Hims & Hers (NYSE: HIMS) ...

Hims & Hers Health (NYSE:HIMS) experienced a 40% increase in share price last quarter, possibly fueled by strong financial performance and future growth projections. The company announced earnings on ...

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) has been assigned a consensus recommendation of “Hold” from the ...

Shares of Hims & Hers Health (NYSE: HIMS) sank 10.5% this week, according to data from S&P Global Market Intelligence. The ...

Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...

Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...

Would you like to be notified of the latest news and updates on the stock market?

With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared ...

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.